In order to test whether your bigger, cheaper screen will help select better drug candidates, you have to measure its ability to predict outcomes at much later stages of the development process.
(Well-known examples of improvements in predictive validity: drugs validated against human genetic targets are more likely to succeed in the clinic. Also, compounds discovered through phenotypic screening are a majority of successful first-in-class drugs.)
-
-
"Optimize predictive validity" seems like really solid logic to me, and I expect it to seem common-sense to a lot of tech people and scientists, but I expect it sounds really "out there" to seasoned biotech execs, so I especially welcome critical feedback from them.
Show this threadThanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.